Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesOff-label uses of biologics in dermatology: Interferon and intravenous immunoglobulin (Part 1 of 2)
Journal of the American Academy of Dermatology, 01/05/07
David I. Smith MD, et al. - The introduction of a number of biologic therapies into the market has revolutionized the practice of dermatology. These therapies include interferons, intravenous immunoglobulin, infliximab, adalimumab, etanercept, efalizumab, alefacept, and rituximab. Most dermatologists are familiar with the Food and Drug Administration–approved indications of these medications
Today in Over The Counter (OTC)...keeping you current
Receive free subspecialty "5-minute updates" via email
Serum Thromboxane B2 Compared to Five Other Platelet Function Tests for the Evaluation of Aspirin Effect in Stable Cardiovascular Disease
Heart, Lung, and Circulation, 03/16/10
Physician Practice Patterns in Acute Coronary Syndromes: An Initial Report of an Individual Quality Improvement Program
Critical Pathways in Cardiology, 03/11/10
Factors influencing intercellular spaces in the esophageal epithelium
World Journal of Gastroenterology, 03/10/10
Article Search
Sponsor
Sponsor